Last Updated : December 1, 2023
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued Sort descending |
---|---|---|---|---|---|---|
Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | |||
Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | |||
Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn | |||
Lemtrada | Alemtuzumab | Multiple sclerosis, relapsing-remitting | Withdrawn | |||
Humira | Adalimumab | ulcerative colitis | Withdrawn | |||
TBC | Darunavir / cobicistat | HIV infection | Withdrawn | |||
Picato | Ingenol mebutate | Actinic keratosis | N/A | Complete | ||
Remsima | Infliximab | Ankylosing spondylitis; arthritis, psoriatic; arthritis, rheumatoid; plaque psoriasis | Withdrawn | |||
Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | |||
Trintellix | Vortioxetine | Depression, major depressive disorder | Withdrawn |